Short answer
CG Oncology, Inc. (CGON) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). PIVOT-006 Phase 3 trial reported unprecedented recurrence-free survival improvement in intermediate-risk and high-grade Ta NMIBC.
CG Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- PIVOT-006 Phase 3 trial reported unprecedented recurrence-free survival improvement in intermediate-risk and high-grade Ta NMIBC
- Positive registrational data could materially strengthen CG Oncology’s path toward regulatory approval and commercial positioning
- Updated corporate presentation signals broader investor communication around the PIVOT-006 results and company strategy
Item 8.01 · Other Events
- Phase 3 PIVOT-006 met its primary endpoint in intermediate-risk and high-grade Ta NMIBC
- Cretostimogene reduced recurrence risk 68% versus control, hazard ratio 0.32, p<0.0001
- Safety favorable: no Grade 3 or greater treatment-related adverse events or treatment-related discontinuations
- BLA submission planned for BCG-unresponsive NMIBC in March 2027, including high-grade papillary-only disease
- Additional BLA planned in Q2 2027 for intermediate-risk and high-grade Ta NMIBC, expanding potential market access
Item EX-99.1 · Exhibit EX-99.1
- PIVOT-006 met its primary endpoint, reducing recurrence risk 68% versus surveillance, with hazard ratio 0.32 and p<0.0001
- Favorable safety profile: no Grade 3-or-higher treatment-related adverse events or treatment-related discontinuations
- 367-patient Phase 3 trial supports a second BLA for intermediate-risk and high-grade Ta NMIBC, targeted for Q2 2027
- Initial BLA scope broadened to include high-grade papillary-only BCG-unresponsive disease, with submission anticipated by March 2027
- Results expand potential commercial opportunity across an approximately 50,000-patient U.S. population lacking FDA-approved adjuvant options
Item EX-99.2 · Exhibit EX-99.2
- PIVOT-006 topline data: 68% RFS improvement, hazard ratio 0.32, p<0.0001
- Results support a second BLA submission for intermediate-risk and high-grade Ta NMIBC, anticipated Q2 2027
- BOND-003 Cohort C: 41.8% complete response at 24 months, with 96.4% progression-free to MIBC
- No Grade ≥3 treatment-related adverse events reported across highlighted cretostimogene programs
- Cretostimogene remains investigational, making regulatory approval and confirmatory data key valuation catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CG Oncology, Inc. 8-K filings
Get the next CGON 8-K as it lands
Follow CGON for push alerts, or ask the research agent what this filing means.